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Synchronous major vessel resection during pancreaticoduodenectomy (PD) for borderline resectable pancreatic adenocarcinoma
remains controversial. In the 1970s, regional pancreatectomy advocated by Fortner was associated with unacceptably high
morbidity and mortality rates, with no impact on long-term survival. With the establishment of a multidisciplinary approach,
improvements in preoperative staging techniques, surgical expertise, and perioperative care reduced mortality rates and improved
5-year-survivalratesarenowachievedfollowingresectioninhigh-volumecentres.Perioperativemorbidityandmortalityfollowing
PD with portal vein resection are comparable to standard PD, with reported 5-year-survival rates of up to 17%. Segmental
resection and reconstruction of the common hepatic artery/proper hepatic artery (CHA/PHA) can be performed to achieve an
R0 resection in selected patients with limited involvement of the CHA/PHA at the origin of the gastroduodenal artery (GDA). PD
withconcomitant majorvessel resectionforborderlineresectable tumoursshouldbeperformedwhenamargin-negative resection
is anticipated at high-volume centres with expertise in complex pancreatic surgery. Where an incomplete (R1 or R2) resection is
likely neoadjuvant treatment with systemic chemotherapy followed by chemoradiation as part of a clinical trial should be oﬀered
to all patients.
Copyright © 2008 O. N. Tucker and M. Rela. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Patients with pancreatic malignancy continue to have a
dismal prognosis determined by the histological classiﬁca-
tion and extent of disease at the time of diagnosis [1].
The prognosis for histologically proven invasive pancreatic
cancer is poor, with a 5-year-survival rate of 9.7% following
resection, and overall median survival time of 8.6 months
[1]. Invasive ductal adenocarcinoma is the most common
epithelial tumour of the exocrine pancreas, of which tubular
adenocarcinoma is the most common histological subtype
[1]. The only potentially curative treatment for invasive
ductal adenocarcinoma is surgical resection. However, only
10–20% of patients are candidates for resection as approx-
imately 50% present with metastatic, and 35% with locally
advanced surgically unresectable disease. Locally advanced,
surgically unresectable proximal pancreatic tumours are
deﬁned as those that encase adjacent arteries including the
coeliac axis, superior mesenteric artery (SMA) or both,
or that occlude the portal vein (PV), superior mesenteric
vein (SMV), or superior mesenteric portal vein (SMPV)
conﬂuence (Tables 1 and 2). This paper reviews the litera-
ture on the management of borderline resectable proximal
pancreatic cancers with vascular involvement with reference
to assessmentof resectability, staging investigations, survival,
pancreaticoduodenectomy (PD) with major arterial and
venous resection and the role of neoadjuvant therapy.
2. DISCUSSION
2.1. Assessmentofresectability
Determining resectability of the primary tumour is the most
important goal in initial patient evaluation. High-quality
computed tomography (CT) scanning can be used to classify
pancreatic tumours into resectable (Stage I or II), locally2 HPB Surgery
Table 1: National comprehensive cancer network practice guide-
lines in oncology for pancreatic adenocarcinoma-v.1.2008: criteria
deﬁning resectability status [2].
Resectable
Head/body/tail tumour
(i) No distant metastases
(ii) Clear fat plane around coeliac and SMA
(iii) Patent SMV/PV
Borderline resectable
Head/body
(i) Severe unilateral SMV/PV impingement
(ii) Tumour abutment on SMA
(iii) GDA encasement up to origin at HA
(iv) Tumours with limited involvement of the IVC
(v) SMV occlusion, if of a short segment, with open vein both
proximally and distally (unresectable if occlusion of the proximal
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(vi) Colon or mesocolon invasion
Tail
(i) Adrenal, colon or mesocolon, kidney invasion
Unresectable
Head
(i) Distant metastases
(ii) SMA, coeliac artery encasement
(iii) SMV/PV occlusion
(iv) Aortic, IVC invasion or encasement
(vi) Invasion of SMV below transverse colon
Body
(i) Distant metastases
(ii) SMA, coeliac, HA encasement
(iii) SMV/PV occlusion
(iv) Aortic invasion
Tail
(i) Distant metastases
(ii) SMA, coeliac encasement
(iii) Rib, vertebral invasion
Nodal status
(i) Metastases to lymph nodes beyond the ﬁeld of resection.
GDA = Gastroduodenal artery
IVC = Inferior vena cava
PV = Portal vein
SMV = Superior mesenteric vein
SMA = Superior mesenteric artery.
advanced, surgically unresectable (Stage III), or metastatic
disease (Stage IV). In recent years, with further advances
in imaging techniques with multidetector CT optimized
for pancreatic imaging, a new subset of tumours have
emerged termed “borderline” or “marginally resectable”
tumours blurring the distinction between resectable and
locally advanced, surgically unresectable tumours [2, 3, 5].
There is currently no consensus in the reported literature
on the deﬁnition or management of borderline resectable
Table 2: M. D. Anderson criteria for deﬁning resectability status of
pancreatic cancer [3, 4].
Resectable
(i) No distant metastases
(ii) No extension to the SMA; normal fat plant between the tumour
and SMA
(iii) No extension to the coeliac axis or HA
(iv) Patent SMV/PV
Borderline resectable
(i) Tumour abutment ≤180◦ (≤50%) of the circumference of the
SMA
(ii) Short-segment encasement/abutment of the CHA (typically at
the GDA origin)
(iii) Short-segment occlusion of the SMV/PV with suitable vessel
above and below
Unresectable
(i) Encased SMA (>180◦)
(ii) Encased HA with no technical option for reconstruction
(iii) Occluded SMV/PV wih no technical option for reconstruction
CHA = common hepatic artery
GDA = Gastroduodenal artery
HA = Hepatic artery
PV = Portal vein
SMV = Superior mesenteric vein
SMA = Superior mesenteric artery.
tumours. The National Comprehensive Cancer Network
(NCCN) recently deﬁned borderline resectable tumours of
the pancreatic head and body as those with severe unilateral
SMV/PV impingement, tumour abutment on SMA, gastro-
duodenal artery (GDA) encasement up to its origin from
the hepatic artery (HA), tumours with limited inferior vena
cava (IVC) involvement, short-segment SMV occlusion with
proximal and distal vein patency, and colon or mesocolon
invasion (Table 1)[ 2]. Tumours are deﬁned as unresectable
in the presence of proximal SMV occlusion up to the PV
branches (Table 1)[ 2]. Neoadjuvant chemoradiotherapy is
advocated by the NCCN for any tumour where an incom-
p l e t eR 1o rR 2r e s e c t i o ni sl i k e l y[ 2]. The M. D. Anderson
criteria for borderline resectable tumours include those with
encasement of a short segment of the HA amenable to
resection and reconstruction without tumour extension to
the coeliac axis, abutment of the SMA involving ≤180◦ of
the arterial circumference, or short-segment occlusion of the
SMV, PV, or SMPV conﬂuence with normal SMV below and
normal PV above the area of tumour involvement amenable
to resection and reconstruction (Table 2)[ 3].
2.2. Staginginvestigations
Multidetector CT imaging is regarded as the optimal diag-
nostic and staging investigation [3, 6–11]. Freeny reported
an accuracy rate of 95–97% for detection of pancreatic car-
cinomas, and 100% for predicting unresectability by helical
CT [12]. In a series of 46 patients with a suspected pancreatic
tumour, Catalano et al. demonstrated sensitivity, speciﬁcity,
and accuracy of multidetector CT of 97%, 80%, and 96%,O. N. Tucker and M. Rela 3
respectively, with correct prediction of unresectability with
sensitivity of 96%, speciﬁcity of 86%, and accuracy of 93%
[13]. However, the ability of helical CT to predict tumour
resectability ranges from 57 to 88% [12, 14, 15]. Its major
limitation is its low sensitivity in the detection of small-
volume disease with nondetection of small-volume hepatic,
serosal and/or peritoneal metastases. Despite advances in
radiological imaging techniques 20–35% of patients thought
tohaveresectabletumourshaveunsuspectedmetastases[15–
18]. In many centres, laparoscopic staging is an integral
component in the preoperative staging protocols of patients
with radiological resectable disease to avoid unnecessary
laparotomy. Biopsy of suspicious liver serosal or peritoneal
metastases inaccessible or too small for interventional radio-
logical techniques can be performed. Extra pancreatic exten-
sion of tumour with colic or mesocolic involvement can be
determined. Improvements in technology and better patient
selection have reduced the beneﬁt of staging laparoscopy.
However, it continues to consistently upstage patients with
preoperative radiologically determined resectable disease
with a beneﬁt in determining resectability of 15–20% [19–
25]. Peritoneal cytology enhances the sensitivity of staging
laparoscopyupstaginganadditional8%ofpatientswithpos-
itive cytology and advanced unresectable pancreatic cancer
[26–28]. In addition, laparoscopic ultrasonography can be
performed to improve the diagnostic accuracy of staging
laparoscopy with evaluation of regional nodal disease, local
vascular involvement, and to search for liver metastases [21,
25, 29–33].
Critics of staging laparoscopy believe inoperable disease
secondary to local extension and vascular encasement can
only be determined by laparotomy [34]. In addition, many
argue that staging laparoscopy is of minimal beneﬁt as
patients with unresectable disease will subsequently require
a bypass procedure for biliary or gastric outlet obstruction.
Historically, reports of the development of obstructive
jaundice in as many as 70% and gastric outlet obstruction
in up to 25% of patients with unresectable pancreatic ade-
nocarcinoma have supported the role of prophylactic bypass
[35–37]. More recent reports suggest a lower incidence of
biliary and gastric outlet obstruction [38]. Also, prophylactic
palliative surgical bypass may be unnecessary. In a study by
Espat et al., only 3% of 155 patients with laparoscopically
staged unresectable histologically proven pancreatic cancer
required a subsequent surgical bypass [39].
Other available investigative tools include mesenteric
angiography, which has been abandoned in most centres in
favour of multidetector CT, magnetic resonance techniques,
transabdominal and endoscopic ultrasonography (EUS),
andintraoperativeintraportalendovascularultrasonography
(IPEUS) [3, 40, 41]. The combination of magnetic reso-
nance cholangiopancreatography and magnetic resonance
angiography has a reported accuracy of 89.7% in predicting
resectability in patients with pancreatic head carcinoma
[42, 43] .E U Sh a sar o l ei nt h ed e t e c t i o no fp a n c r e a t i c
cancer, tissue conﬁrmation of malignancy by EUS-directed
ﬁne needle aspiration (EUS-FNA), and determination of
tumour resectability by assessment of locoregional tumour
extension [44–50]. EUS has been advocated as the most
sensitive method to assess small lesions <2cm in diameter
[47]. In a series by Brandwein et al., the ﬁnding of a focal
hypoechoic mass without other abnormalities predicted
malignancy in patients with ductal adenocarcinoma with an
accuracy of 89%, speciﬁcity of only 22.2%, and sensitivity of
100% as all patients with a pancreatic mass were evaluated
[46]. Findings at EUS predicted tumour resectability with
an accuracy of 85%, speciﬁcity of 75%, and sensitivity of
100%, and EUS-FNA correctly detected malignancy with
an accuracy of 65%, speciﬁcity of 100%, and sensitivity
of 59.5% [46]. Sensitivity and speciﬁcity rates of EUS for
conﬁrming venous invasion range from 69% to 93% and
71% to 100%, respectively [51–53]. Sensitivities of 59.5%
to 91% have been reported with EUS-FNA in the diagnosis
of pancreatic malignancy [46, 54, 55]. To avoid the risk of
tumourseedingalongneedletractsEUS-FNAispreferableto
percutaneous approaches. The presence of a cytologist at the
time of the EUS with immediate evaluation of the EUS-FNA
specimen increases the accuracy of the procedure. However,
cytologicalinterpretation of thetissuesamplecanbediﬃcult
due to the presence of reactive atypia or a benign appearance
of pancreatic ductal cells in a well diﬀerentiated pancreatic
adenocarcinoma.
Intraoperative intraportal endovascular ultrasonography
(IPEUS) is employed in a limited number of centres to assess
locoregional tumour extension, in particular PV invasion
and invasion of the second portion of the pancreatic head
nerve plexus [56, 57]. Invasion of the extrapancreatic nerve
plexus is common in pancreatic head adenocarcinoma. In
thesecases,achievementofanR0resectionwouldnecessitate
complete dissection of the extrapancreatic nerve plexus
and the nerve plexus around the SMA resulting in severe
diarrhoea. Nakao et al. advocate the use of IPEUS to evaluate
for extrapancreatic nerve plexus invasion. In the absence of
invasion of the second portion of the pancreatic head nerve
plexus preservation of the left semicircular nerve plexus
around the SMA is recommended to prevent the occurrence
of postoperative diarrhoea [57]. In the presence of extra-
pancreatic nerve plexus invasion particularly to the nerve
plexus around the SMA radical resection is contraindicated
[57].
2.3. Survival
T h eg o a lo fs u r g e r yi st oa c h i e v ea nR 0r e s e c t i o n .M a r g i n
resection status is an important prognostic factor, and
a margin-positive resection predicts early recurrence and
reduced survival [3, 40, 58]. Previous reports suggest that
patients with a positive surgical margin following PD have
a similar survival rate to patients with locally advanced,
surgically unresectable disease treated nonoperatively with
5-ﬂuorouracil-based chemotherapy and irradiation [10, 57].
However, in some series, statistically signiﬁcantly longer
overall survival rates have been reported after palliative
PD for pancreatic head, neck, and uncinate process adeno-
carcinoma than palliative surgical bypass or nonoperative
candidates when performed in high-volume centres with
minimal morbidity and mortality, and combined with
adjuvant chemoradiotherapy [59, 60].4 HPB Surgery
Historically, major vessel involvement has been a con-
traindication to resection in patients with pancreatic adeno-
carcinoma. In 1973, Fortner described a surgical approach
of regional pancreatectomy involving en bloc resection
of peripancreatic soft tissue, regional lymph nodes with
resection of the PV (Type I), or resection and reconstruction
of a major artery (Type II) [61]. Although these extended
resections achieved improved resectability rates, associated
highmorbidity(67%)andmortality(23%)withlowsurvival
rates (3-year-survival rate 3%) discouraged generalized
adoption of major vessel resection and reconstruction.
However, since the 1970s there have been major advances in
radiological and surgical techniques resulting in improved
preoperative staging, better patient selection, and reduced
surgical morbidity and mortality [3, 62]. Perioperative
mortality rates of less than 4% following PD are now
achieved in high-volume centres [1, 40, 58]. In a consecutive
series of 650 PD procedures performed between 1990 and
1996 at The Johns Hopkins Medical Institute, the mortality
rate was 1.4%, with a reoperation rate for complications of
4%, and a mean hospital length of stay of 13 days [63]. No
death was observed in the last 190 consecutive patients who
underwent PD [63].
2.4. Pancreaticoduodenectomywithmajor
arterialresection
Tumour encasement or abutment >180◦ of the arterial cir-
cumference of the SMA, or encasement of the coeliac or HA
remain contraindications to resection (Tables 1 and 2)[ 2, 3].
Tumour encasement of the SMA or coeliac artery usually
predicts extensive involvement of the mesenteric neural
plexus with an inability to achieve a negative retroperitoneal
resection margin even with radical extended surgery [3,
57]. PD with a histologically proven positive retroperitoneal
marginperformedaspartofastandardorextendedresection
is associated with a median survival of less than one year
[10]. Major arterial resection and reconstruction has been
associated with a high operative mortality and morbidity in
some series with poor long-term outcome [40]. A tumour is
deemed unresectable if the HA is encased with no technical
option for reconstruction due to extension to the coeliac
axis/splenic/left gastric junction or coeliac origin (Tables 1
and 2)[ 2, 3]. Borderline unresectable tumours with arterial
involvement include those with tumour abutment of ≤180◦
of the circumference of the SMA, tumour encasement of
the GDA up to its originat the HA, or short-segment
encasement/abutment of the common hepatic artery(CHA)
or proper hepatic artery (PHA)typically at the GDA origin.
Segmental resection of the HA with reconstruction is usually
possible by primary end-to-end anastomosis because of the
redundancy of the artery, or by an interposition graft. This
limited involvement of the CHA/PHA is typically due to
tumour extension in a cephalad direction along the GDA.
More subtle ﬁndings on multidetector CT can be helpful in
determining tumour resectability. The ability to achieve an
R0 or R1 surgical resection is more likely in the presence of
periarterial stranding rather than dense tissue involving the
artery [3].
2.5. Pancreaticoduodenectomywithmajor
venousresection
There are two important questions to ask when considering
PD with PV resection. Can PV resection be performed safely
a n dd o e sS M V / P Vi n v o l v e m e n ta ﬀect long-term survival?
These questions have been addressed in the published liter-
ature. In contrast to arterial resection, PD with PV resection
can be performed safely with no increase in perioperative
morbidity or mortality compared to standard PD [40, 57,
58, 64, 65]. Although in some studies PV resection has
been associated with longer operative time, higher blood
loss, greater transfusion requirements, and a longer length of
hospital stay, reported operative morbidity and mortality is
comparabletostandardPD[40,58,64–68].Arecentseriesby
Yekebas et al. demonstrated no statistical diﬀerence in oper-
ative time, intraoperative blood transfusion requirements,
vascular complications, in hospital morbidity or mortality
rates in 128 patients who underwent en bloc vascular
resection compared to 449 undergoing standard resection
[11]. This series of 585 consecutive patients included those
with pancreatic, ampullary, and distal common bile duct
cancers who underwent potentially curative resection over
an 11-year-period [11]. Final histopathology conﬁrmed
pancreatic ductal adenocarcinoma in 482 of 585 patients
(82%) of which 100 (21%) underwent vascular resection
[11]. In a series by Bachellier et al., one of 31 patients died of
mesentericvenousinfarction4daysfollowingPDwithSMV-
PV resection resulting in a mortality rate of 3.2% [69, 70].
Of 21 patients who underwent PD with SMV-PV resection
in the same series from 1994 no postoperative deaths were
observed [69, 70]. In Van Geenen’s et al., series of 250
consecutive PDs 34 (16%) underwent SMV-PV resection, of
which 28 had a tangential wedge and 6 a segmental resection
[69, 70]. The overall mortality for the series was 1.2%, with
a 0% mortality after SMV-PV resection in the 34 patients
[69, 70]. Although the numbers are small, these reports
demonstrate the feasibility and safety of PD with SMV-PV
resection when performed in centres with acceptable overall
morbidity and mortality rates following standard PD. In
a recently published series by Nakao et al., major vessel
resection was performed in 201 of 289 (69%) patients who
underwent curative resection for invasive ductal carcinoma
of the pancreas from 1981 to 2005 [40]. This group performs
combined resection of major vessels including the PV and
visceral arteries if involved with catheter bypass of the
PV, extrapancreatic nerve plexus excision, and extended
lymphadenectomy including the paraaortic lymph nodes
with retroperitoneal connective tissue clearance. PV or SMV
resection was performed in 200 patients, combined PV and
arterialresectionin14,andhepaticarterialresectionwithout
PV resection in one patient [40]. Operative mortality was
3.8% for the 289 patients who underwent resection, 1.1% for
patients without vascular resection, 2.7% for patients with
SMV/PV resection, and 35.7% for combined PV and arterial
resection [40]. The combined PV and arterial resection
group had a higher operative death rate, more advanced
tumours, and a higher incidence of positive dissected
peripancreatic tissue margins [40].O. N. Tucker and M. Rela 5
Involvement of the SMV, PV, or SMPV conﬂuence are
not associated with histological variables predicting a poor
prognosis [64]. Involvement of the SMPV conﬂuence is
thought to be a function of tumour location and size rather
than an indicator of aggressive tumour biology [1, 64]. 5-
year-survival rates of 7.4% to 17% have been reported in
patients following PD with PV resection [1, 11, 57, 65].
However, 5-year-survival rates after PD with PV resection
are signiﬁcantly better after an R0 resection than an R1
or R2 resection [1, 40]. A higher incidence of perineural
invasion and a greater median tumour size has been
reported in a small number of studies in patients requiring
PV resection [64, 65]. However, these variables have no
statistically signiﬁcant inﬂuence on survival when analysed
in univariate or multivariate analysis [11, 65]. Importantly,
patients who require PV resection in the absence of tumour
extension to the SMA or coeliac axis have similar survival
to patients undergoing standard PD [10, 71]. Nakao et al.
have reported improved cumulative 5-year-survival rates
in patients with tumour-free margins after PD with PV
resection even in the presence of tumour invasion of the
SMV-PV with a negative arterial margin [40]. Complete
PV encasement with occlusion and thrombosis remains a
contraindication to resection as arterial involvement is likely.
It is important to note that PV resection in published
series has been performed for clinical and/or radiological
suspicion of PV involvement. Pancreatic adenocarcinoma is
known to induce an extensive desmoplastic stromal reaction
in surrounding tissues. Therefore, it can be diﬃcult to
distinguish true PV invasion from tumour adherence to
the PV by an inﬂammatory reaction both on preoperative
imaging and intraoperatively. Importantly, the absence of
histological PV invasion is reported in 18% to 50% of
cases with intraoperatively suspected vascular inﬁltration
[11, 58, 65, 66, 69, 71–77]. Recently published series
report peritumoural inﬂammatory adherence to the vein
wall in 23% of patients suspected of vascular invasion [11,
71].
While PV resection itself is not a negative prognostic
indicator, histologically proven PV invasion is independently
correlated with lower patient survival [11, 57, 68]. Patients
who undergo PV resection without true invasion of the
vein wall have better survival than those with histologically
proven PV invasion [11, 57, 68]. In the presence of negative
dissected peripancreatic tissue margins, 2-year-survival is
reduced in patients with histologically proven positive PV
wall invasion following extended PD [57] .T h ed e g r e eo fP V
wall invasion correlates with outcome with reduced survival
as the depth of invasion increases [68]. In a report by
Nakagohri et al., 60% of patients with invasion of the tunica
intima of the PV had extrapancreatic nerve plexus involve-
ment [78] .I nar e c e n ts t u d y ,R i e d i g e re ta l .r e p o r t e d5 - y e a r -
survival rates following PD with PV resection for pancreatic
head cancer of only 11% in the presence of histologically
proven malignant PV invasion compared to 51% for those
without venous invasion [58]. However, this result should be
interpreted with caution as it represents a subgroup analysis
in a total of 14 and 12 patients, respectively [58]. Other
groups report equivalent median survival of patients with
histopathologicallyconﬁrmedvascularinvasioncomparedto
those without vascular invasion [11, 66, 76, 77].
2.6. Theroleofneoadjuvanttherapy
To maximize the potential for an R0 resection, Varad-
hachary et al. advocate neoadjuvant treatment with systemic
chemotherapy followed by chemoradiation in patients with
borderline resectable tumours deﬁned by the extent of local
tumour growth on multidetector CT [3]. Following a 6 to
8 month course of neoadjuvant treatment, patients with
responding or stable disease undergo PD with vascular
resection if required. Varadhachary et al. describe their
institutional experience with the use of diﬀering protocols of
neoadjuvant systemic therapy followed by chemoradiation,
and four representative cases are presented [3]. Recent
reports suggesting improved response rates, with acceptable
tolerability and short-term outcome with gemcitabine-
based chemoradiation neoadjuvant treatment protocols are
promising [3, 79–83]. The optimal regimen of preoperative
treatment has not been deﬁned to date, and is the subject
of ongoing clinical research trials. Detailed analysis of data
from the Eastern Cooperative Oncology Group (ECOG
1200) phase II prospective multicentre study is awaited [84].
This study was designed to determine the eﬃcacy of 2
neodajuvant chemoradiotherapeutic regimes, and the eﬀect
on margin-resection status in patients with locally advanced,
potentially resectable pancreatic adenocarcinoma. Patients
were randomized to receive neoadjuvant gemcitabine and
radiotherapy or gemcitabine, ﬂuorouracil, and cisplatin fol-
lowed by radiotherapy and ﬂuorouracil, followed by surgery
and adjuvant chemotherapy [84]. Locoregional adjuvant
chemotherapy may be of beneﬁt in patients with positive PV
margins following extended PD with PV resection. In a pilot
studyofpostoperativeintra-arterialchemotherapyimproved
survival to 25.6 months in patients following PV resection
with histologically proven PV invasion was demonstrated
versus 9.4 months without chemotherapy through reduction
in the occurrence of liver metastasis [85]. Although the
results of this study need to be interpreted with caution due
to its small size further trials in this area are warranted.
3. CONCLUSION
Major vessel involvement should not be considered a
contraindication to resection of borderline resectable pan-
creatic adenocarcinoma when a margin-negative resection
is anticipated, and the procedure is performed in a high-
volumecentrewithacceptablemorbidityandmortalityrates.
In our institution, all patients with suspected SMV/PV
involvement in the absence of distant metastatic disease,
where segmental resection and reconstruction are feasible,
are considered candidates for PD with concomitant major
vessel resection. Tumour encasement of the SMA, coeliac
or HA remains contraindications to resection due to the
inability to achieve a margin negative resection, and high
operative mortality and morbidity. Patients with limited
involvement of the CHA/PHA due to tumour extension in a
cephalad direction along the GDA are considered candidates6 HPB Surgery
for PD with concomitant major vessel resection where
segmental resection and reconstruction are feasible with
minimal morbidity and mortality. Neoadjuvant treatment
with systemic chemotherapy followed by chemoradiation as
part of a clinical trial should be oﬀered to all patients with
borderline resectable tumours when an incomplete (R1 or
R2) resection is anticipated.
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